Hepatitis C, new updates

Further updates have been made to the list of regional centers authorized to prescribe medicinal products for the treatment of hepatitis C. The active ingredients involved are telaprevir, boceprevir, sofosbuvir and simeprevir. The list of approved centers to prescribe medicinal products based on eculizumab for the treatment of atypical hemolytic uremic syndrome has also been updated, which is no longer included in the list of medicines dispensed and paid entirely by the National Health Service. As of 22nd February last year, it is no longer possible to register new patients for this indication in the registers of drugs undergoing monitoring, while for patients already registered monitoring will continue in the same way until the end of the treatment. The monitoring register for medicinal products based on aflibercept has been published for the indication: treatment in adults for visual impairment due to diabetic macular edema. The register will be available from 15th March next and the medicine will be able to be used for this indication in the system for reimbursement.